We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 29, 2021

Rivaroxaban vs Low-Dose Aspirin in Patients With Type 2 Diabetes and High Cardiovascular Risk



Additional Info

Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers
Diabetologia 2021 Dec 01;64(12)2701-2712, F Pistrosch, JB Matschke, D Schipp, B Schipp, E Henkel, I Weigmann, J Sradnick, SR Bornstein, AL Birkenfeld, M Hanefeld

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading